An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas

• Histologically confirmed adenocarcinoma of pancreas not previously treated in metastatic setting
• Initial diagnosis of metastatic disease < or = 6 weeks prior to screening
• Measurable disease
• ECOG PS 0-1
• Adequate hepatic, hemtologic, and renal function
• No prior therapy in adjuvant setting unless adjuvant therapy was completed at least 12 months prior to metastatic diagnosis
• No CNS metastases

• Primary- OS
• Secondary- PFS, ORR